secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bellerophon Therapeutics, Inc. (—)
CIK:        0001600132
Form:       8-K
Filed at:   2023-08-07T23:59:59+00:00
Accession:  0001104659-23-088330
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Bellerophon CEO Peter Fernandes and VP Parag Shah to depart under separation agreements
--------------------------------------------------------------------------------

- CEO Peter Fernandes' separation effective Nov 15, 2023; receives lump sums of $205,950 plus two $102,975 payments.
- VP Parag Shah's separation effective Aug 31, 2023; receives $140,600 upfront and $140,600 later.
- Both will perform transition duties until separation dates and have signed release of claims and non-solicit covenants.
- No successor or interim appointments announced for either departing executive.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1600132/000110465923088330/0001104659-23-088330-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1600132/000110465923088330/tm2322999d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-088330

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer